Advice

following a full submission:
 
ospemifene (Senshio®) accepted for use within NHSScotland.

Indication under review: Treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy.

Ospemifene was associated with significant improvements in physiological parameters (including vaginal maturation index and vaginal pH), and generally associated with improved patient reported symptom scores for vaginal dryness and dyspareunia compared with placebo in patients with VVA.

Medicine details

Medicine name:
ospemifene (Senshio)
SMC ID:
SMC2170
Indication:

For the treatment of moderate to severe symptomatic vulvar and vaginal atrophy in post-menopausal women who are not candidates for local vaginal oestrogen therapy.

Pharmaceutical company
Shionogi Limited
BNF chapter
Endocrine system
Submission type
Full
Status
Accepted
Date advice published:
09 September 2019